VaxGen(Brisbane, California) reported that it has entered into an amended lease agreement to secure space to support the production of its recombinant anthrax vaccine.

The new lease replaces VaxGen’s previous sublease for about 50,000 square feet and provides an additional 25,000 square feet of new space for immediate use and another 30,000 square feet that the company plans to occupy over the next six months.

The space, which totals 105,000 square feet, will be used for quality assurance, quality control, research and development and other functions.

VaxGen makes biologic products for the prevention and treatment of infectious diseases, including developing vaccines against smallpox, as well as anthrax.